secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0000950170-23-004644
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen reports FY2022 revenue $140.7M, net loss $293.7M; China roxadustat sales up 74%
--------------------------------------------------------------------------------

- Total revenue $140.7M in 2022 vs $235.3M in 2021 (which included $120M milestone from Astellas).
- Net loss $293.7M ($3.14 per share) vs $290.0M prior year; Q4 net loss $66.2M ($0.70 per share).
- China roxadustat net product revenue $82.9M in 2022, up 74% YoY; Q4 $23.4M, up 328% YoY.
- Cash, equivalents, investments, and AR $442.7M at Dec 31, 2022; funded into 2H 2024.
- Five pivotal Phase 3 readouts expected in 2023: pamrevlumab in DMD and IPF, roxadustat in MDS and CIA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/fgen-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer